What Makes Daxxify Different?
Peptide-Exchange Technology for Longer-Lasting Results
Daxxify (daxibotulinumtoxinA-lanm) is the only FDA-approved neuromodulator that uses a proprietary stabilizing peptide — RTP004 — instead of human serum albumin as a carrier protein. This peptide anchors the toxin to the target nerve junction more effectively than traditional carrier systems, resulting in a longer duration of action. In pivotal clinical trials, the median duration of response for Daxxify in the glabellar region was 24 weeks — six months — with many patients experiencing results up to nine months. For Sioux City patients who previously received Botox every three to four months, Daxxify typically means two treatments per year instead of three or four.
FDA-approved for glabellar lines (11s); used off-label for forehead and crow's feet
Median duration: 6 months; up to 9 months in many patients
Peptide-exchange carrier technology — no albumin
$6/unit — cost-effective over a full year
Consistent, natural-looking results in Sioux City clinical practice
Prosper Health's preferred neuromodulator for most patients
